Regeneron Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.06.18	Regeneron, Zoetis Announce Research Collaboration - Quick Facts (RTTNews)
06.06.18	Regeneron and Zoetis Announce Collaboration to Research Antibody Therapies for Use in Animal Health (PR Newswire)
04.06.18	New England Journal of Medicine Publishes Pivotal Cemiplimab Trials Showing Positive Results in Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
04.06.18	New England Journal of Medicine publishes pivotal cemiplimab trials showing positive results in advanced cutaneous squamous cell carcinoma (PR Newswire)
31.05.18	Regeneron's Investigational Ebola Treatment Shipping to Democratic Republic of the Congo for Use in Current Outbreak (PR Newswire)
21.05.18	New England Journal of Medicine publishes two positive Phase 3 trials showing Dupixent® (dupilumab) improved moderate-to-severe asthma (PR Newswire)
21.05.18	New England Journal of Medicine Publishes Two Positive Phase 3 Trials Showing DUPIXENT® (dupilumab) Improved Moderate-to-Severe Asthma (PR Newswire)
18.05.18	Regeneron Announces Upcoming Investor Conference Presentation (PR Newswire)
16.05.18	Regeneron and Sanofi Share First Positive Clinical Data for Cemiplimab in Advanced Non-small Cell Lung Cancer at ASCO (PR Newswire)
16.05.18	Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis (PR Newswire)
16.05.18	Regeneron, Sanofi: Phase 3 Dupixent Trial Meets Primary, Key Secondary Endpoints (RTTNews)
16.05.18	Positive Phase 3 Trial of DUPIXENT® (dupilumab) in Adolescents with Inadequately Controlled Moderate-to-severe Atopic Dermatitis (PR Newswire)
03.05.18	Regeneron Pharmaceuticals Q1 adjusted earnings Beat Estimates (RTTNews)
03.05.18	Regeneron Reports First Quarter 2018 Financial and Operating Results (PR Newswire)
02.05.18	DocPanel Announces Partnership with the University of Southern California Keck School of Medicine (PR Newswire)
01.05.18	2018 Global Channel Report Reveals Clients Attacked Mostly Through Privileged Accounts (PR Newswire)
01.05.18	Sanofi, Renegeron To Lower Net Price Of Praluent Injection - Quick Facts (RTTNews)
01.05.18	Sanofi and Regeneron to lower net price of Praluent® (alirocumab) Injection in exchange for straightforward, more affordable patient access for Express Scripts patients (PR Newswire)
01.05.18	Regeneron and Sanofi to Lower Net Price of Praluent® (alirocumab) Injection in Exchange for Straightforward, More Affordable Patient Access for Express Scripts Patients (PR Newswire)
01.05.18	INGN Soars On Revised Outlook, MRK Faces FDA In Sep., KPTI Taken By STORM (RTTNews)
30.04.18	Regeneron And Sanofi Say FDA Accepts Priority Review BLA For Cemiplimab (RTTNews)
30.04.18	FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
30.04.18	FDA to Conduct Priority Review of Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
23.04.18	Regeneron Announces Upcoming Investor Conference Presentations (PR Newswire)
18.04.18	ARTiFACTS and Blockchain in Healthcare Today Partner to Expand Use of Blockchain in Scholarly Publishing (PR Newswire)
09.04.18	Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018 (PR Newswire)
06.04.18	American Financial Benefits Center on Debt-Free College and Existing Repayment Options (PR Newswire)
03.04.18	Regeneron And Sanofi Say EMA Accepts For Review Application For DUPIXEN (RTTNews)
03.04.18	EMA to Review DUPIXENT® (dupilumab) as Potential Treatment for Inadequately Controlled Moderate-to-Severe Asthma (PR Newswire)
03.04.18	EMA to Review Cemiplimab as a Potential Treatment for Advanced Cutaneous Squamous Cell Carcinoma (PR Newswire)
03.04.18	Caroline S. Koblenzer is recognized by Continental Who's Who (PR Newswire)
22.03.18	FENC On Fast Track, SPHS To Report Data In Q2, REGN, ALNY Team Up For NASH (RTTNews)
21.03.18	Regeneron and Alnylam Pharmaceuticals Announce Collaboration to Discover New Treatments for Nonalcoholic Steatohepatitis (NASH) (PR Newswire)
21.03.18	Regeneron Genetics Center® Publication in New England Journal of Medicine Identifies New Genetic Variant Providing Protection from Chronic Liver Disease (PR Newswire)
19.03.18	Regeneron Reports Positive Results From Phase 3 PANORAMA Trial With EYLEA (RTTNews)
19.03.18	EYLEA® (aflibercept) Injection Demonstrates Positive Topline Results in Phase 3 Non-Proliferative Diabetic Retinopathy Trial (PR Newswire)
14.03.18	Teen Scientists Win $1.8 Million at Regeneron Science Talent Search 2018 with Top Awards for Novel Research on Crop Blight, Vaping and Rare Disease (PR Newswire)
12.03.18	SVRA Disappoints, SNY/REGN's Praluent Price To Be Cut, OBSV On Watch (RTTNews)
11.03.18	An Ear To The Pharma: 4 Stocks To Watch This Week (RTTNews)
10.03.18	Regeneron, Sanofi To Cut Heart Drug's Price; Say Praluent Lowers Risk Of Death (RTTNews)
10.03.18	Sanofi and Regeneron announce plans to make Praluent® more accessible and affordable for patients with the greatest health risk and unmet need (PR Newswire)
10.03.18	Regeneron and Sanofi Announce Plans to Make Praluent® (alirocumab) More Accessible and Affordable for Patients with the Greatest Health Risk and Unmet Need (PR Newswire)
10.03.18	Praluent® (alirocumab) Injection significantly reduced risk of cardiovascular events in high-risk patients, and was associated with lower death rate (PR Newswire)
10.03.18	Praluent® (alirocumab) Injection Significantly Reduced Risk of Cardiovascular Events in High-Risk Patients, and was Associated with Lower Death Rate (PR Newswire)
04.03.18	An Ear To The Pharma: 7 Stocks To Watch This Week (RTTNews)
02.03.18	Sanofi: FDA prüft Antrag für Dupilumab für Asthma-Behandlung (Dow Jones)
02.03.18	Sanofi:FDA Reviews DUPIXENT As Potential Treatment For Moderate-to-Severe Asthma (RTTNews)
02.03.18	FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma (PR Newswire)
12.02.18	Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial (PR Newswire)
08.02.18	Regeneron Pharmaceuticals Q4 Income Rises (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

24.12.24		Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu
24.12.24		Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone
19.12.24		Optimismus in New York: NASDAQ 100 startet im Plus
17.12.24		Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge
17.12.24		Minuszeichen in New York: NASDAQ 100 verliert nachmittags
17.12.24		Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer
12.12.24		Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer
12.12.24		Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

24.12.24

Börse New York: NASDAQ 100-Anleger greifen am Dienstagmittag zu

24.12.24

Dienstagshandel in New York: NASDAQ 100 startet in der Gewinnzone

19.12.24

Optimismus in New York: NASDAQ 100 startet im Plus

17.12.24

Schwacher Wochentag in New York: NASDAQ 100 verbucht letztendlich Abschläge

17.12.24

Minuszeichen in New York: NASDAQ 100 verliert nachmittags

17.12.24

Zurückhaltung in New York: NASDAQ 100 präsentiert sich schwächer

12.12.24

Schwache Performance in New York: NASDAQ 100 zeigt sich schlussendlich schwächer

12.12.24

Angespannte Stimmung in New York: NASDAQ 100 präsentiert sich schwächer

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

UBS Group	27.65	2.14 %	K V
Novartis	88.82	1.30 %	K V
Part Grp Hldg	1’233.00	1.23 %	K V
Kuehne+Nagel Int	207.50	1.22 %	K V
Lonza Grp	538.00	1.05 %	K V
Swisscom	503.00	0.40 %	K V
Sonova Hldg	296.60	0.34 %	K V
Swiss Life Hldg	697.40	0.11 %	K V
Zurich Insur Gr	539.60	0.11 %	K V
Holcim	87.40	0.02 %	K V

Nachrichten zu Regeneron Pharmaceuticals Inc.

Aktien Top/Flop

Regeneron Pharmaceuticals Peer Group Nachrichten

Meistgelesene Nachrichten